TY - JOUR
AU - Figueiredo, Eberval Gadelha
AB - Neurocrit Care (2022) 37:813–814 https://doi.org/10.1007/s12028-022-01589-x LE T TERS TO THE EDITOR Intravenous Nimodipine Versus Enteral Nimodipine: The Meta-analysis Paradox 1 2* 3 Leonardo Christian Welling , Nicollas Nunes Rabelo , Lucas Bezerra de Aguiar and Eberval Gadelha Figueiredo © 2022 Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society To the Editor: given intravenously? Why the choice of the outcome in We congratulate Geraldini et al. [1] on the study recently 3  months? Were rehabilitation variables and socioeco- published in Neurocritical Care. With unparalleled clar- nomic and hospital conditions controlled at different ity, care was taken in choosing the best tools for analyzing times and in different countries? As much as methodo - the works included in its meta-analysis and systematic logical and statistical rigor was included in the presented review. Particularly in the supplementary material, atten- study, such variables can never be controlled. tion is drawn to the caution and significant effort the Nevertheless, what are the meta-analyses that can sta- authors have made to make their answers as clear as pos- tistically compile results from previous studies? If well- sible. Intravenous and oral nimodipine had similar clini- designed studies support a hypothesis, the compilation of 
TI - Intravenous Nimodipine Versus Enteral Nimodipine: The Meta-analysis Paradox
JF - Neurocritical Care
DO - 10.1007/s12028-022-01589-x
DA - 2022-12-01
UR - https://www.deepdyve.com/lp/springer-journals/intravenous-nimodipine-versus-enteral-nimodipine-the-meta-analysis-oTBAkkKQxh
SP - 813
EP - 814
VL - 37
IS - 3
DP - DeepDyve
ER -